Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
Ab175494-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $109.90 | |
Ab175494-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $519.90 | |
Ab175494-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,399.90 | |
Ab175494-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,239.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
Product Name | Clazakizumab (anti-IL-6) - Primary antibody, specific to IL6, >95% (SDS-PAGE&SEC), high purity, Human IgG1 |
---|---|
Synonyms | ALD-518;ALD518;BMS-945429 |
Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
Biochemical and Physiological Mechanisms | Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. It indu |
Specificity | IL6 |
Conjugation | Unconjugated |
Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
Action Type | INHIBITOR |
Mechanism of action | INHIBITOR of Interleukin-6 inhibitor |
Product Description | Clazakizumab (anti-IL-6) is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab (anti-IL-6) may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab (anti-IL-6) can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection. |
Isotype | Human IgG1 |
---|---|
Light Chain Type | kappa |
SDS-PAGE | 145.24 kDa |
Purification Method | Protein A purified |
Purity | >95% (SDS-PAGE&SEC) |
Form | Liquid |
Concentration | Lot by Lot |
Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
Shipped In | Ice chest + Ice pads |
Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
CAS | 1236278-28-6 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IMGT/mAb-DB | 414 |
---|---|
Wikipedia | Clazakizumab |
Enter Lot Number to search for COA:
1. Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR. (2011) A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer.. Expert Opin Biol Ther, 11 (12): (1663-8). [PMID:21995322] |
2. Mease PJ, Gottlieb AB, Berman A, Drescher E, Xing J, Wong R, Banerjee S. (2016) The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis.. Arthritis Rheumatol, 68 (9): (2163-73). [PMID:27059799] |
3. Ma JD, Heavey SF, Revta C, Roeland EJ. (2014) Novel investigational biologics for the treatment of cancer cachexia.. Expert Opin Biol Ther, 14 (8): (1113-20). [PMID:24707881] |
4. FitzGerald O. (2016) Spondyloarthropathies: IL-6 blockade in psoriatic arthritis - a new therapeutic option?. Nat Rev Rheumatol, 12 (6): (318-9). [PMID:27215204] |
5. Weinblatt ME, Mease P, Mysler E, Takeuchi T, Drescher E, Berman A, Xing J, Zilberstein M, Banerjee S, Emery P. (2015) The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study.. Arthritis Rheumatol, 67 (10): (2591-600). [PMID:26138593] |